Molecular targeting in acute myeloid leukemia

Acute myeloid leukemia (AML) is a heterogenous disease associated with distinct genetic and molecular abnormalities. Somatic mutations result in dysregulation of intracellular signaling pathways, epigenetics, and apoptosis of the leukemia cells. Understanding the basis for the dysregulated processes provides the platform for the design of novel targeted therapy for AML patients. The effort to devise new targeted therapy has been helped by recent advances in methods for high-throughput genomic screening and the availability of computer-assisted techniques for the design of novel agents that are predicted to specifically inhibit the mutant molecules involved in these intracellular events. In this review, we will provide the scientific basis for targeting the dysregulated molecular mechanisms and discuss the agents currently being investigated, alone or in combination with chemotherapy, for treating patients with AML. Successes in molecular targeting will ultimately change the treatment paradigm for the disease.

Abstract licence: CC BY-NC-ND

1. 6.

   BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells · 2015

2. 55.

   Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application · 2013

86 more references, whose wording the paper’s licence keeps private.

• Small molecules in targeted cancer therapy: advances, challenges, and future perspectives · 2021

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.